Ayaka Hashimoto
Overview
Explore the profile of Ayaka Hashimoto including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
63
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kajiyoshi M, Yamamoto T, Arima T, Mufalo W, Hashimoto A, Oumi T, et al.
Chemosphere
. 2024 Aug;
363:142985.
PMID: 39089339
The adsorption layer system has shown great potential as a cost-effective and practical strategy for the recycling and management of excavated rocks containing potentially toxic elements (PTEs). Although this system...
2.
Okuyama Y, Okajima A, Sakamoto N, Hashimoto A, Tanabe R, Kawajiri A, et al.
Biochem Biophys Res Commun
. 2022 Nov;
637:9-16.
PMID: 36375254
Group 2 innate lymphoid cells (ILC2s) are resident cells and participate in innate and adaptive immunity. In the tumor microenvironment (TME), ILC2s contribute to both tumorigenesis and inhibition of tumor...
3.
Hashimoto A, Tezuka F, Yamashita K, Morimoto M, Sugiura K, Takeuchi M, et al.
NMC Case Rep J
. 2022 Jan;
8(1):221-227.
PMID: 35079467
A 74-year-old man presented with symptoms of intermittent claudication. A diagnosis of lumbar spinal canal stenosis (LSS) at L3/4 and L4/5 was made based on the clinical and radiological findings....
4.
Kamei N, Hashimoto A, Tanaka E, Murata K, Yamaguchi M, Yokoyama N, et al.
Drug Deliv Transl Res
. 2022 Jan;
12(11):2667-2677.
PMID: 35015254
Antibody drugs that target amyloid β (Aβ) are considered possible treatments for Alzheimer's disease; however, most have been dropped from clinical trials. We hypothesized that administration route for antiAβ antibody...
5.
Kamei N, Suwabe S, Arime K, Bando H, Murata K, Yamaguchi M, et al.
Pharmaceutics
. 2021 Nov;
13(11).
PMID: 34834159
We previously found that coadministering peptides and proteins with the cell-penetrating peptide L-penetratin intranasally significantly increased transport to the brain and enhanced pharmacological effects. The present study aimed to clarify...
6.
Takeuchi M, Yamashita K, Hashimoto A, Takamatsu N, Sugiura K, Manabe H, et al.
Neurol Med Chir (Tokyo)
. 2021 Jan;
61(2):144-151.
PMID: 33390418
Transforaminal full-endoscopic spine (TF-FES) surgery is minimally invasive and can be performed under local anesthesia. Thus, it is expected that the patient can return to work (RTW) quickly. However, information...
7.
Narita N, Okumura K, Kinjo T, Mikami J, Tsushima K, Takahashi R, et al.
Circ J
. 2020 Mar;
84(5):706-713.
PMID: 32213724
Background: Direct oral anticoagulants (DOACs) are effective in reducing thromboembolism events in patients with non-valvular atrial fibrillation (NVAF). However, little is known about trends in NVAF prevalence and DOAC prescriptions...
8.
Maeda T, Takamatsu N, Hashimoto A, Omichi Y, Sugiura K, Ishihama Y, et al.
J Spine Surg
. 2020 Mar;
6(Suppl 1):S300-S306.
PMID: 32195437
Transforaminal endoscopic discectomy has been established as the least minimally invasive spine surgical procedure because it avoids the surgical morbidity from surgical dissection and denervation of normal anatomy responsible for...
9.
Sairyo K, Yamashita K, Manabe H, Ishihama Y, Sugiura K, Tezuka F, et al.
J Med Invest
. 2019 Oct;
66(3.4):224-229.
PMID: 31656278
Full-endoscopic spinal surgery was first developed for the lumbar herniated nucleus pulposus. Mainly, there are two types in the full-endoscopic lumbar surgery : i.e., transforaminal (TF) and interlaminar approach. The...
10.
Aso Y, Hashimoto A, Ohara H
Curr Microbiol
. 2019 Jul;
76(10):1186-1192.
PMID: 31302724
Bioprocess development is a current requirement to enhance the global production of D-lactic acid. Herein, we report a new bioprocess for D-lactic acid production directly from starch using engineered Lactococcus...